Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Medidur for non-infectious posterior uveitis – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Uveitis is an inflammation that affects the lining of the eye. It can lead to eye pain, eye redness, headaches, and problems with vision that can become permanent. It may be caused by an infection, but in many cases the cause of uveitis is unknown.
Medidur is a new drug implant that is injected straight into the back of the eye. It releases a corticosteroid drug called fluocinolone acetonide for as long as 3 years. Corticosteroids are already used to treat uveitis, but need to be taken daily as tablets or injected into the eye on regular occasions.
If Medidur is licensed for use in the UK, it could be a new treatment option for patients with uveitis. It could be particularly helpful for patients who are not responding to standard drug treatments and to try to reduce the risk of the disease returning. Indexing Status Subject indexing assigned by CRD MeSH Adrenal Cortex Hormones; Drug Implants; Eye Pain; Humans; Uveitis, Posterior Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000813 Date abstract record published 22/06/2016 |